Edition:
India

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

15.77USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$15.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
155,664
52-wk High
$18.35
52-wk Low
$12.25

Chart for

About

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery... (more)

Overall

Beta: 2.13
Market Cap(Mil.): $893.29
Shares Outstanding(Mil.): 54.14
Dividend: --
Yield (%): --

Financials

BRIEF-Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

05 Dec 2017

BRIEF-Heron Therapeutics Announces Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

05 Dec 2017

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

10 Nov 2017

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

06 Nov 2017

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

26 Oct 2017

BRIEF-Heron Therapeutics initiates phase 3 program for HTX-011

* Heron Therapeutics announces initiation of phase 3 program for HTX-011 in postoperative pain following successful end-of-phase 2 meeting with FDA

10 Aug 2017

BRIEF-Heron Therapeutics reports quarterly loss per share $0.80

* Heron Therapeutics reports financial results for the three and six months ended June 30, 2017 and recent corporate progress

10 Aug 2017

Earnings vs. Estimates